Go to main content

The scarcity of organs for patients that need transplants has led to exceedingly lengthy waits for organ transplants for sick patients. Fabrication of tissues and organ constructs in-vitro has potential to end the shortage, however many of the machines used to create these tissues and organs are expensive, not easy to use, and do not have any further practical applications. Bioprinting technology has the potential to revolutionize the fabrication of biological constructs that can be used as in vitro model tissues and vivo substitutes. Bioprinting is the process of using conventional 3D printing methods and computer-aided-design (CAD) to create patient and user specific constructs with biological material. 3D printers are ideal for low volume customizable parts, and when these parts can be made of living cells and biomaterials these machines become ideal for cell based research. Converting commercially available 3D printers into biomanufacturing units answers several problems that are faced by researchers, namely: the ability to create 3D multicomponent system creating multicellular interfaces in cell culture, and the ability to study cells in a true 3D environment. Although biological tissues have a range of cell types and material properties, current bioprinting methods are limited in their ability to print multiple materials simultaneously, especially tissues with vastly different material properties. For instance, printing of soft gels alongside a hard-structural material remains a challenge, as the thermal, mechanical, and biochemical parameters during the printing process must be maintained in an appropriate range to ensure high viability of living cells. Therefore, to truly realize the potential of bioprinting within the biomedical community, new capabilities that allow multi-material bioprinting are needed. The goal of this work is to enable four capabilities using commercially available inexpensive 3D printers: (i) printing of new thermoplastics, (ii) printing of structural thermoplastic material alongside soft biomaterials (iii) printing two soft biomaterials and/or cell types using conventional extrusion printing, and (iv) printing soft biomaterials that do not possess the necessary material properties for conventional extrusion printing. Results from this work will democratize bioprinting technology by driving down the cost of entry into the field, and will enable its use in solving important challenges in the field of tissue engineering.